

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

## **ARTICLE IN PRESS**

Médecine et maladies infectieuses xxx (2020) xxx-xxx



Disponible en ligne sur

**ScienceDirect** 

www.sciencedirect.com

Letter to the editor

Interleukin-6 as a potential biomarker of COVID-19 progression

ARTICLE INFO

*Keywords:* COVID-19 IL-6 Biomarker

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), also known as the 2019 novel Coronavirus (2019-nCoV), has caused a recent outbreak of Coronavirus Disease (COVID-19) [1,2]. To date, COVID-19 has already affected 372,757 people globally, with a 4.35% mortality rate. In Indonesia, the first case of COVID-19 was reported on March 2, 2020. Since then, the number of positive cases has risen significantly to 686 cases, according to government data on March 23, 2020.

Although most cases were mild to moderate, some patients developed severe symptoms characterized by respiratory dysfunction and/or multiple organ failure [3]. In the current situation, identification of COVID-19 disease progression mainly relies on the clinical manifestation, while no effective biomarker has been proposed. It has been suggested that one of the possible mechanisms underlying rapid disease progression is a cytokine storm [1,2]. Previous retrospective studies indicated that an elevated level of interleukin-6 (IL-6) was associated with a high case fatality of COVID-19 infection [1]. Thus, a meta-analysis of the current scientific literature was performed to investigate whether the measurement of serum IL-6 may predict disease progression of COVID-19 patients.

A comprehensive literature search was conducted from PubMed, Scopus, Web of Science, and Google Scholar. Keywords such as "IL-6", "coronavirus 2019/COVID-19", "2019-nCoV", "SARS-CoV-2" were used on their own or in combination without applying language restriction and dated up to March 25, 2020. Selection criteria were case-control or cohort studies evaluating serum IL-6 levels in COVID-19 patients with or without severe condition (*i.e.*, the period of infection, CT score, ICU admission, troponin levels, those needing mechanical ventilation, or those who died). A metaanalysis was performed using a random-effect model to allow for heterogeneity in individual studies. Hedge's standardized mean difference (SMD) with 95% confidence interval (CI) was used to assess the IL-6 level in non-severe and severe patients. Heterogeneity Elsevier Masson France



EM consulte www.em-consulte.com

was evaluated with Q-test and l<sup>2</sup> statistics. Begg's funnel plot and Egger's regression test were applied to determine publication bias if the pooled effect size consisted of 10 or more studies. A sensitivity test was performed by sequentially omitting one study each time to evaluate the stability of the results. Data that was not expressed as mean and standard deviation was extrapolated from the sample size, median, and interquartile range (IQR). The meta-analysis was performed using RevMan version 5.3 and the value of 0.05 was indicative of statistical significance.

We initially identified 73 articles based on our search strategy, 64 of which were excluded after title, abstract, or full-text reading, because they were review articles, did not report IL-6 levels, or did not classify the condition of COVID-19 patients as non-severe and severe. Finally, only nine studies were included in this meta-analysis [1–9]. Although the heterogeneity was considerably high ( $I^2 = 89\%$ ; P < 0.00001), we observed that IL-6 levels were significantly increased in COVID-19-infected patients with severe condition compared with those with non-severe condition (SMD=0.71, 95%CI -0.31-1.12, P=0.0005) (Fig. 1), Begg's funnel plot (data not shown) and Egger's test were performed, and no publication bias was observed (P Egger's test=0.117). A sensitivity analysis was conducted by eliminating one individual study each time (Fig. 2). However, the results remained unchanged, suggesting that the findings were statistically stable and robust.

Cytokines are vital in regulating immunological and inflammatory responses. Among them, IL-6 is of major importance because of its pleiotropic effects [1]. Here, we presented the evidence that circulating IL-6 levels are closely linked to the severity of COVID-19 infection. An increase in IL-6 levels has previously been observed in patients with respiratory dysfunction [2], implying a possible shared mechanism of cytokine-mediated lung damage caused by COVID-9 infection. Furthermore, it seems that the highly pathogenic SARS-CoV-2 is associated with rapid virus replication and a tendency to infect the lower respiratory tract, resulting in an elevated response of IL-6-induced severe respiratory distress. Thus, our results suggest that serial measurement of circulating IL-6 levels may be important in identifying disease progression among COVID-19-infected patients. In line with our findings, an elevated level of IL-6 has been proven to be a good biomarker for severity of hepatitis B virus (HBV) infection [10]. Therefore, it is reasonable that immediate initial evaluation of IL-6 level be performed upon hospital admission of COVID-19 patients, due to its potential benefits to assess worsening clinical features and disease progression in COVID-19.

https://doi.org/10.1016/j.medmal.2020.04.002 0399-077X/© 2020 Elsevier Masson SAS. All rights reserved.

# **ARTICLE IN PRESS**

Letter to the editor / Médecine et maladies infectieuses xxx (2020) xxx-xxx

	Severe			Non-severe			Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% CI
Chen et al	64	63.92	17	10.4	20.14	21	8.2%	1.16 [0.47, 1.86]	
Gao et al	36.1	26.81	15	10.6	14.11	28	8.2%	1.29 [0.60, 1.98]	
Liu et al (1)	3.3	1.18	25	4.7	2.44	25	8.9%	-0.72 [-1.29, -0.15]	
Liu et al (2)	4.6	20.88	7	0	5.4	44	7.6%	0.51 [-0.29, 1.31]	
Liu et al (a)	52	11	9	34	7	15	6.3%	2.00 [0.97, 3.04]	
Liu et al (b)	108	12	5	34	7	15	1.5%	8.46 [5.37, 11.56]	,
Qin et al	25.2	33.25	286	13.3	27.55	166	10.5%	0.38 [0.19, 0.57]	-
Wang et al	17.2	24.96	50	9.7	13.18	115	10.0%	0.42 [0.09, 0.76]	
Wu et al (a)	7.4	3.64	63	6.76	4	48	9.9%	0.17 [-0.21, 0.54]	-+
Wu et al (b)	7.4	3.64	63	7.36	2.62	77	10.0%	0.01 [-0.32, 0.35]	
Yang et al	14.61	16.23	34	8.06	7.57	21	9.0%	0.47 [-0.08, 1.03]	
Zhou et al	11	5.11	54	6.3	2.14	137	10.0%	1.44 [1.09, 1.78]	
Total (95% CI)			628			712	100.0%	0.71 [0.31, 1.12]	-
Heterogeneity: Tau <sup>2</sup> = 0.39; Chi <sup>2</sup> = 100.24, df = 11 (P < 0.00001); l <sup>2</sup> = 89%									
Test for overall effect: Z = 3.46 (P = 0.0005) -2 -1 0 1 2									

Fig. 1. Forest plot for pooled standardized mean difference (SMD) and 95% confidence interval (95% CI) of circulating IL-6 levels in COVID-19-infected patients with severe and non-severe condition.




Fig. 2. Sensitivity analysis of changes in IL-6 levels of COVID-19-infected patients.

## Human and animal rights

The authors declare that the work described has not involved experimentation on humans or animals.

#### Informed consent and patient details

The authors declare that the work described does not involve patients or volunteers.

#### Funding

This work did not receive any grant from funding agencies in the public, commercial, or not-for-profit sectors.

## Author contributions

All authors attest that they meet the current International Committee of Medical Journal Editors (ICMJE) criteria for Authorship.

## **Disclosure of interest**

The authors declare that they have no competing interest.

## References

 Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng J, et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. bioRxiv 2020, http://dx.doi.org/10.1101/2020.02.29.20029520.

- [2] Wang H, Luo S, Shen Y, Li M, Zhang Z, Dong Y, et al. Multiple enzyme release, inflammation storm and hypercoagulability are prominent indicators for disease progression in COVID-19: a multi-centered, correlation study with CT imaging score. SSRN 2020, http://dx.doi.org/10.2139/ssrn.3544837.
- [3] Yang P, Ding Y, Xu Z, Pu R, Li P, Yan J, et al. Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China. bioRxiv 2020, http://dx.doi.org/10.1101/2020.02.28.20028068.
- [4] Liu J, Ouyang L, Guo P, Wu HS, Fu P, Chen YL, et al. Epidemiological, clinical characteristics and outcome of medical staff infected with COVID-19 in Wuhan, China: A retrospective case series analysis. bioRxiv 2020, http://dx.doi.org/10.1101/2020.03.09.20033118.
- [5] Zhou F, Yu T, Du R, Fan 4, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020, http://dx.doi.org/10.1016/S0140-6736(20)30566-3 [pii: S0140-6736(20)30566-3].
- [6] Wu C, Hu X, Song J, Du C, Xu J, Yang D, et al. Heart injury signs are associated with higher and earlier mortality in coronavirus disease 2019 (COVID-19). bioRxiv 2020, http://dx.doi.org/10.1101/2020.02.26.20028589.
- [7] Liu L, Gao JY, Hu W, Zhang X, Guo L, Liu CQ, et al. Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing, China. bioRxiv 2020, http://dx.doi.org/10.1101/2020.02.20.20025536.
- [8] Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19. J Med Virol 2020, http://dx.doi.org/10.1002/jmv.25770.
- [9] Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020, http://dx.doi.org/10.1093/cid/ciaa248 [pii: ciaa248].
- [10] Xia C, Liu Y, Chen Z, Zheng M. Involvement of Interleukin 6 in Hepatitis B Viral Infection. Cell Physiol Biochem 2015;37(2):677–86, http://dx.doi.org/10.1159/000430386.

Zulvikar Syambani Ulhaq<sup>a,1,\*</sup> Gita Vita Soraya<sup>b,1</sup>

Please cite this article in press as: Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. Med Mal Infect (2020), https://doi.org/10.1016/j.medmal.2020.04.002

2

#### Letter to the editor / Médecine et maladies infectieuses xxx (2020) xxx-xxx

<sup>1</sup> Both authors contributed equally to this manuscript.

Received 3 April 2020

Accepted 3 April 2020 Available online xxx

 <sup>a</sup> Department of Biomedical Science, Faculty of Medicine and Health Sciences, Maulana, Malik Ibrahim Islamic State University of Malang, 65151 Batu, East Java, Indonesia
<sup>b</sup> Department of Biochemistry, Faculty of Medicine, Hasanuddin University, 90245 Makassar, South Sulawesi, Indonesia

\* Corresponding author. *E-mail address:* zulhaq@kedokteran.uin-malang.ac.id (Z.S. Ulhaq)

Please cite this article in press as: Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. Med Mal Infect (2020), https://doi.org/10.1016/j.medmal.2020.04.002